Diving into Batch-to-Batch Variability of Topical Products-a Regulatory Bottleneck

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery
• Regulatory Science

Background:

• The European Medicine Agency (EMA) has proposed new guidelines for assessing the quality and equivalence of topical products.
• These guidelines require sameness in qualitative, quantitative, microstructure, and performance aspects for generic topical applications.
• The strictness and suitability of these new regulatory limits are currently under debate within the scientific community.

Purpose of the Study:

• To characterize a panel of eight reference blockbuster semisolid topical products.
• To evaluate the suitability of current EMA draft guidelines for bioequivalence assessment of topical semisolid products.
• To identify key factors contributing to product variability in semisolid topical formulations.

Main Methods:

• Characterization of three batches per product, including different manufacturing sites where possible.
• Assessment of product microstructure (globule size, pH, rheology, thermal behavior) and in vitro release testing (IVRT).
• Integrated multivariate analysis to determine features contributing most to product variability.

Main Results:

• Significant differences were observed within reference semisolid topical products.
• Application of EMA criteria indicated that none of the same product batches met equivalence standards.
• Rheological parameters and IVRT indicators were identified as major contributors to batch-to-batch variability.

Conclusions:

• Semisolid dosage forms inherently possess significant variability.
• The study underscores the necessity for establishing more reasonable and practical equivalence criteria for generic topical drug products.
• Current regulatory limits may require re-evaluation to accurately reflect the intrinsic variability of semisolid formulations.